Can I Take Ashwagandha with Repatha (Evolocumab)?

How Repatha (Evolocumab) Works and Why It Matters for Supplement Safety

Repatha is a fully human monoclonal antibody (IgG2) that inhibits proprotein convertase subtilisin/kexin type 9 (PCSK9), a serine protease that degrades LDL receptors on hepatocytes. By blocking PCSK9, evolocumab keeps LDL receptors available on the liver surface, which allows more LDL-cholesterol to be cleared from the bloodstream. In the FOURIER trial (N=27,564), evolocumab 140 mg every two weeks reduced LDL-C by 59% from baseline and cut major adverse cardiovascular events by 15% over a median 2.2 years [1].

Biologic Clearance vs. Small-Molecule Metabolism

This distinction changes the supplement-interaction equation entirely. Small-molecule statins are metabolized by CYP3A4, CYP2C9, and related enzymes, making them vulnerable to inhibition or induction by botanical compounds. Evolocumab, by contrast, is a 144-kDa protein antibody. It follows target-mediated drug disposition (TMDD): a portion binds to circulating PCSK9, while the remainder is cleared by non-specific proteolytic catabolism, the same pathway used to break down endogenous IgG [2]. No CYP enzyme, P-glycoprotein transporter, or hepatic first-pass metabolism applies.

What the FDA Label Says About Drug Interactions

The FDA-approved prescribing information for evolocumab contains no listed drug-drug interactions and no warnings about herbal supplements [3]. The agency's clinical pharmacology review concluded that cytochrome P450-based interactions are not expected given the biologic nature of the molecule. That absence of a warning does not mean supplements are irrelevant to patients on evolocumab; it means the concern shifts from pharmacokinetics to pharmacodynamics.

What Ashwagandha Does in the Body

Ashwagandha (Withania somnifera) root and root extract contains a family of withanolide steroidal lactones plus alkaloids, saponins, and iron. Its primary studied effects in humans span four areas: cortisol reduction, thyroid hormone modulation, testosterone support, and modest lipid changes. Understanding each domain helps clarify where biologically meaningful overlap with evolocumab therapy could plausibly occur.

Cortisol and HPA Axis Effects

A 2012 double-blind RCT (N=64) published in the Indian Journal of Psychological Medicine found that KSM-66 ashwagandha root extract 300 mg twice daily for 60 days reduced serum cortisol by 27.9% compared to placebo (P<0.001) [4]. A second 8-week RCT (N=60) confirmed a 22.2% cortisol reduction with the same extract [5]. Chronically elevated cortisol independently raises LDL-C and triglycerides through upregulated hepatic lipogenesis and impaired LDL receptor expression. Lowering cortisol could, in theory, produce a small additive LDL-lowering effect alongside evolocumab, though the magnitude would be far smaller than evolocumab's 59% reduction.

Thyroid Hormone Modulation

A 2018 randomized controlled trial (N=50) in the Journal of Alternative and Complementary Medicine showed that 600 mg/day of ashwagandha root extract for 8 weeks significantly increased serum T3 (triiodothyronine) by 41.5% and T4 (thyroxine) by 19.6% in adults with subclinical hypothyroidism [6]. Thyroid hormones regulate hepatic LDL receptor density through sterol regulatory element-binding protein (SREBP) pathways. Elevated T3 increases LDL receptor transcription, which is the same upstream mechanism that PCSK9 inhibitors exploit by preventing receptor degradation. The pathways are complementary rather than antagonistic, but a clinician managing a patient's cardiovascular risk profile needs to know about both.

Lipid Effects of Ashwagandha Itself

A small but growing body of RCT data suggests ashwagandha has a direct, modest lipid effect. A 2009 pilot study (N=18) in the Journal of the American Nutraceutical Association reported reductions of approximately 9.7 mg/dL in total cholesterol and 8.2 mg/dL in LDL-C after 30 days of ashwagandha root powder 3 g/day [7]. These numbers are clinically small relative to the 70-100 mg/dL LDL reductions evolocumab produces in high-risk patients, but they illustrate that the supplement is not lipid-inert.

Is There a Direct Pharmacokinetic Interaction?

No. Based on the molecular biology of both substances, a pharmacokinetic interaction between ashwagandha and evolocumab is not expected.

Why Evolocumab Bypasses the CYP System

Evolocumab's TMDD clearance and IgG catabolism pathway are not influenced by CYP1A2, CYP2C9, CYP2C19, CYP3A4, or CYP2D6 [3]. Ashwagandha withanolides, including withaferin A, have been studied for CYP inhibition in vitro. A 2011 study found mild inhibitory activity against CYP3A4 in hepatic microsomes [8]. Even if that in vitro signal were clinically relevant for small molecules, it would not apply to a biologic cleared by proteolysis.

Bioavailability of Ashwagandha Itself

Ashwagandha is taken orally; its withanolides undergo intestinal absorption and first-pass hepatic metabolism. Evolocumab is administered subcutaneously, bypassing the gastrointestinal tract entirely. The two compounds do not share absorption compartments, further reducing any pharmacokinetic concern.

Pharmacodynamic Overlap: Where Clinicians Should Pay Attention

The practical clinical concern is pharmacodynamic, not pharmacokinetic. Three overlapping biological pathways deserve attention.

Pathway 1: LDL Receptor Regulation

Ashwagandha's cortisol-lowering and thyroid-stimulating actions both increase hepatic LDL receptor density through distinct mechanisms. Evolocumab prevents PCSK9-mediated degradation of those same receptors. The combination could produce additive LDL receptor upregulation. In a patient already at an LDL-C goal of <55 mg/dL (the ESC/EAS 2021 target for very-high cardiovascular risk), pushing LDL even lower theoretically raises the question of whether very low LDL carries long-term risks. The FOURIER and ODYSSEY OUTCOMES trial data did not identify safety signals at mean LDL-C levels around 30 mg/dL [1][9], so this overlap is unlikely to be harmful, but it should be tracked.

Pathway 2: Testosterone and Androgen Biology

A 2019 RCT in Medicine (N=43) found that ashwagandha 600 mg/day for 8 weeks increased serum testosterone by 14.7% in healthy men [10]. Androgens influence hepatic lipid metabolism; testosterone at physiological levels increases LDL receptor activity, which again aligns directionally with evolocumab's mechanism. Patients taking testosterone replacement therapy alongside evolocumab and ashwagandha represent a population where monitoring lipid panels more frequently, at 3-month intervals rather than annually, seems clinically reasonable.

Pathway 3: Inflammatory and Immune Modulation

Evolocumab's cardiovascular benefit tracks with LDL-C reduction, but some researchers have examined whether PCSK9 itself has inflammatory roles. A 2020 review in the European Heart Journal noted that PCSK9 may modulate toll-like receptor signaling and sepsis pathways [11]. Ashwagandha's withanolides, particularly withaferin A, inhibit NF-kB activation in vitro [12]. Whether this dual anti-inflammatory action produces any net change in evolocumab's clinical effectiveness has not been studied in human trials.

Monitoring Recommendations for Patients Taking Both

The following framework reflects current evidence gaps and standard cardiovascular care practice. No clinical trial has studied this specific combination. Monitoring recommendations are based on the pharmacodynamic overlap signals described above.

Lipid Panel Monitoring

A fasting lipid panel at baseline and at 3 months after starting ashwagandha is appropriate for patients already established on evolocumab. The American Heart Association advises repeat lipid measurement 4-12 weeks after any significant change in lipid-modifying therapy [13]. Adding a supplement with documented lipid activity qualifies as such a change. If LDL-C falls below 30 mg/dL, discuss with your cardiologist whether the evolocumab dose or dosing interval warrants review.

Thyroid Function Testing

Patients with pre-existing thyroid conditions or those on levothyroxine should obtain a TSH and free T4 at baseline before starting ashwagandha, then repeat at 8 weeks. The 2018 RCT demonstrating 41.5% T3 increase [6] used 600 mg/day, a dose matching most commercial KSM-66 products. Clinically significant thyroid over-stimulation is rare in euthyroid individuals but remains a concern in borderline hypothyroid patients.

Liver Enzymes and Hepatotoxicity Signal

Rare cases of ashwagandha-associated hepatotoxicity have been reported in the literature. A 2023 case series in the American Journal of Case Reports documented five patients with acute liver injury temporally linked to ashwagandha supplementation, with resolution after discontinuation [14]. Evolocumab's FDA label does not list hepatotoxicity as a concern, and the drug does not raise liver enzymes in clinical trials [3]. Still, obtaining a baseline ALT/AST before starting ashwagandha in any patient on complex cardiovascular therapy is prudent.

What Ashwagandha Users Are Actually Taking: Dose and Product Variation

Commercial ashwagandha products range from 250 mg to 1,500 mg per serving, use varying extract ratios (5:1 to 20:1), and may or may not specify withanolide content. The most studied standardized extracts are KSM-66 (5% withanolides) and Sensoril (10% withanolides). Because ashwagandha is classified as a dietary supplement under the Dietary Supplement Health and Education Act of 1994, it does not require FDA pre-market approval for safety or efficacy [15]. Third-party tested products carrying NSF International or USP certification reduce contamination risk.

Why Dose Matters for Interaction Risk

The thyroid-stimulating effect documented in the 2018 RCT used 600 mg/day of root extract [6]. Lower doses (250-300 mg/day) used for stress and sleep may produce smaller hormonal shifts. Patients using high-dose ashwagandha stacks (above 1,000 mg/day) warrant closer monitoring of both thyroid and lipid parameters.

What Leading Cardiologists and Guidelines Say

The 2022 ACC/AHA Guideline on Cardiovascular Disease Prevention states: "Clinicians should ask about all dietary supplements, including herbals, at every visit, as some may have effects on lipid levels, blood pressure, or drug metabolism relevant to cardiovascular risk management" [16].

A statement from the American Heart Association's Council on Lifestyle and Cardiometabolic Health notes that "the evidence base for most dietary supplements in established cardiovascular disease remains insufficient to support routine recommendation or contraindication, and individualized risk-benefit discussion is warranted" [13].

Neither guideline specifically addresses ashwagandha and PCSK9 inhibitors, which reflects how recent PCSK9 inhibitor use has become in broader clinical practice and how limited supplement-biologic interaction research remains.

Clinical Decision Summary: Should You Take Ashwagandha with Repatha?

The answer is not a blanket prohibition, nor a blanket green light. The pharmacokinetic safety profile of this combination is favorable because evolocumab does not use CYP pathways. The pharmacodynamic picture is more nuanced. Ashwagandha modestly lowers cortisol, raises thyroid hormones, may reduce LDL-C by 8-10 mg/dL, and influences androgen levels. These effects run in the same directional lane as evolocumab's LDL-lowering mechanism, creating an additive rather than opposing pharmacodynamic profile.

The Patients Who Need the Most Caution

Four groups warrant closer scrutiny before combining ashwagandha with evolocumab:

• Patients with subclinical or overt hypothyroidism also taking levothyroxine
• Men on concurrent testosterone replacement therapy
• Patients with elevated liver enzymes at baseline
• Anyone using high-dose ashwagandha above 900 mg/day of standardized extract

The Patients Where the Combination Appears Low-Risk

Euthyroid adults without pre-existing liver disease taking a standard 300-600 mg/day KSM-66 or Sensoril product alongside evolocumab 140 mg every two weeks represent the lowest-risk profile. The most reasonable step for this group is disclosure to their cardiologist, a baseline lipid panel and TSH, and a repeat lipid panel at 3 months.